Immunotherapy for advanced prostate cancer: A novel treatment option to improve survival

Managed Care

Volumn 20, Issue 9, 2011, Pages 3-11

  Peskin, Steven R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; SIPULEUCEL T; TISSUE EXTRACT;

AGE; ARTICLE; BONE TUMOR; COST; ECONOMICS; HOSPITALIZATION; HUMAN; IMMUNOTHERAPY; MALE; METASTASIS; METHODOLOGY; MORTALITY; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR; SURVIVAL; TUMOR RECURRENCE; UNITED STATES;

AGE FACTORS; BONE NEOPLASMS; CANCER VACCINES; COSTS AND COST ANALYSIS; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TISSUE EXTRACTS; UNITED STATES;

EID: 84555220516     PISSN: 10623388     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (47)

1. ACS (American Cancer Society). Cancer Facts and Figures 2011. Atlanta: American Cancer Society. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdfcancer. Accessed Aug. 29, 2011a.
2. ACS (American Cancer Society). Prostate cancer. http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/index. Accessed Aug. 29, 2011b.
3. Alam S, McNeel DG. DNA vaccines for the treatment of prostate cancer. Expert Rev Vaccines. 2010;9:731-745.
4. Basler M, Groettrup M. Advances in prostate cancer immunotherapies. Drugs Aging. 2007;24:197-221.
5. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007; 110(9):1959-1966.
6. Chamie K, DeVere White RW, Lee D, et al. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer. 2008;113:2464-2470.
7. CMS (Centers for Medicare and Medicaid Services). Decision Memo for Autologous Cellular Immunity Treatment of Metastatic Prostatic Cancer (CAG-00422N). June 30, 2011a. http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=247&ver=12&NcaName=Autologous+Cellular+Immunotherapy+TreatmentofMetastaticProstateCancer. Accessed Aug. 29, 2011.
8. CMS (Centers for Medicare and Medicaid Services). CMS Manual System, Pub 100-04 Medicare Claims Processing. July 8, 2011b. https://www.cms.gov/transmittals/downloads/R2254CP.pdf. Accessed Aug. 29, 2011.
9. Crawford ED, Black L, Eaddy M, Kruep EJ. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(2):162-167.
10. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371(9625):1710-1721.
11. Dendreon Corporation. Data on file. Seattle: Dendreon Corp; 2011.
12. Di Lorenzo G, Buonerba C, Autorino R, et al. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs. 2010;70(8):983-1000.
13. Doehn C, Bohmer T, Kausch I, et al. Prostate cancer vaccines: current status and future potential. BioDrugs. 2008;22(2):71-84.
14. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nature Rev Immunol. 2010;10:580-593.
15. FDA (US Food and Drug Administration). FDA Approves a cellular immunotherapy for men with advanced prostate cancer [press release]. Washington, DC: US Food and Drug Admininstration; April 29, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.html. Accessed Aug. 29, 2011.
16. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670 -3679.
17. Higano CS, Small EJ, Schellhammer PF, et al. Survival consistency in study subpopulations and predictors of outcome from the integrated analysis of sipuleucel-T trials in metastatic castration resistant prostate cancer [poster]. Presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2010; Chicago.
18. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994;180:1-4.
19. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2008/; based on November 2010 SEER data submission; posted to the SEER Web site in 2011.
20. Jayadevappa R, Schwartz JS, Chatre S, et al. The burden of out-of-pocket and indirect costs of prostate cancer. Prostate. 2010;70(11):1255-1264.
21. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225-249.
22. Jevtana (cabazitaxel) Injection [prescribing information]. Bridgewater, NJ: Sanofi-aventis US; June 2010.
23. Kalinski P, Urban J, Narang R, et al. Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol. 2009;5:379-390.
24. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
25. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
26. Kawachi MH, Bahnson RR, Barry M, et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J NCCN. 2010; 8:240-262.
27. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J NCCN. 2010;8:162-200.
28. NCI (National Cancer Institute). Treatment choices for men with earlystage prostate cancer. Bethesda, MD: National Cancer Institute, National Institutes of Health, US Dept of Health and Human Services; 2005. http://www.cancer.gov/cancertopics/treatment/prostate/understanding-prostate-cancer-treatment/page1. Accessed Aug. 29, 2011.
29. NCI (National Cancer Institute). Cancer Trends Progress Report - 2009/2010 Update, National Cancer Institute. Bethesda, MD: National Institutes of Health, US Dept of Health and Human Services; April 2010. http://progressreport.cancer.gov. Accessed Aug. 29, 2011.
30. NCI (National Cancer Institute). Surveillance Epidemiology and End Results. SEER stat fact sheets: prostate. http://seer.cancer.gov/statfacts/html/prost.html. Accessed Aug. 29, 2011.
31. Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother. 2008;42(1):91-98.
32. Penson DF, Rossignol M, Sartor AO, et al. Prostate cancer: epidemiology and health-related quality of life. Urology. 2008;72(6 suppl):S3-11.
33. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
34. Provenge (sipuleucel-T) [prescribing information]. Seattle: Dendreon Corporation; April 2011.
35. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
36. Sheikh NA, dela Rosa C, Stewart FP, et al. Sipuleucel-T treatment results in sequential ex vivo activation of APCs and T cells during the culture step-evidence for in vivo immunological priming [poster]. Presented at the 2010 American Association for Cancer Research (AACR) 101st Annual Meeting; April 17-21, 2010; Washington, DC.
37. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24:1967-2000.
38. Skolarus TA, Zhang Y, Miller DC, et al. The economic burden of prostate cancer survivorship care. J Urol. 2010;184:532-538.
39. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094.
40. Sowery RD, So AL, Gleave ME. Therapeutic options in advanced prostate cancer: present and future. Curr Urol Rep. 2007;8:53-59.
41. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27:5431-5438.
42. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
43. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
44. Valone FH, Small E, MacKenzie M, et al. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 2001;7(suppl 2):S53-S61.
45. Vieweg J. Immunotherapy for advanced prostate cancer. Rev Immunol. 2007;9:1:S29-S38.
46. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy, part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 2005;15:181-186.
47. Wesley JD, Chadwick E, Kuan LY, et al. Characterization of antigen specific T-cell activation and cytokine expression induced by sipuleucel-T [poster]. Presented at the 2010 International Society for Biological Therapy of Cancer (iSBTc) Annual Meeting; Sept. 30-October 4, 2010; Washington, DC.